Sign In
Buy NKTR
$59.23
+0.670 (+1.14%)
At Close: Jun 03, 2026
73% of the NKTR-255 treatment group compared to 50% of the placebo group achieved a complete response at 6 months NKTR-255 enhanced CAR T-cell kinetics with improved CD8+ CAR-T area under the curve (A
- NKTR-422 demonstrated inflammation resolution and tissue repair in multiple preclinical models of chronic inflammatory conditions - SAN FRANCISCO , Nov. 18, 2024 /PRNewswire/ -- Nektar Therapeutics
Multiple Catalysts Ahead For Nektar Therapeutics
09:11am, Thursday, 14'th Nov 2024
Nektar continues to make progress with rezpegaldesleukin, with results from the phase 2 atopic dermatitis study expected in H1'25. NKTR-255 is showing promising results in multiple oncology trials, al
Nektar Q3 Loss Narrower Than Expected, Pipeline Development in Focus
01:05pm, Friday, 08'th Nov 2024
NKTR reports encouraging third-quarter results as both earnings and revenues beat estimates. Product sales increase year over year.
Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates
06:41pm, Thursday, 07'th Nov 2024
Nektar Therapeutics (NKTR) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.19 per share a year ago.
Nektar Therapeutics Reports Third Quarter 2024 Financial Results
04:15pm, Thursday, 07'th Nov 2024
SAN FRANCISCO , Nov. 7, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2024. Cash and investments in marketable secu
– NKTR-255 administered post completion of concurrent chemoradiation and in combination with durvalumab demonstrated statistically significant lymphocyte recovery compared to historical controls at
Nektar Therapeutics to Participate in Upcoming Investor Conferences
06:00pm, Wednesday, 06'th Nov 2024
SAN FRANCISCO , Nov. 6, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the upcoming conferences: UBS Global Healthcare
Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential
01:44pm, Monday, 04'th Nov 2024
Piper Sandler has initiated coverage on Nektar Therapeutics Inc NKTR, citing the company's lead asset rezpegaldesleukin's (REZPEG) differentiated mechanism of action.
Huntsville-based facility to be spun out as standalone Ampersand portfolio company. Nektar to receive $90 million in total consideration for the business, comprised of $70 million in cash and $20 mill
SAN FRANCISCO , Oct. 31, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2024 on Thursday, November 7, 2024, after the close of U.S.-b
- Data from multiple Phase 1b studies in inflammatory skin conditions demonstrate durable dose-dependent improvements in physician-assessed disease activity and patient-reported outcomes - - Biomarker
– Relapse-free/progression-free survival for NKTR-255 plus CD19-22 CAR-T cell therapy at 12 months was double that of historical controls (67% vs 38%) – – Eight of nine patients achieved comple
Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024
03:30am, Wednesday, 25'th Sep 2024
- New proteomic analyses show that rezpegaldesleukin increases the protein levels of immune-regulating pathways while reducing specific serum proteins known to be elevated in patients with atopic derm
Nektar Management to Present at Upcoming Investor Conferences
09:00am, Tuesday, 03'rd Sep 2024
SAN FRANCISCO , Sept. 3, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at upcoming investor conferences: H.C.
